Posted by Korean ingredient supplier BTC Corporation is promoting FermenGIN®, a bioconverted red ginseng extract that combines enzymatic pre-digestion of ginsenosides with γ-cyclodextrin microencapsulation. A new white paper released in October 2026 puts the cyclodextrin component front and centre.
Ginseng’s two unresolved problems
Ginseng (Panax ginseng) is one of the best-selling botanicals worldwide, yet formulators have long struggled with two of its properties. The first is bioavailability: the major ginsenosides in red ginseng are large, heavily glycosylated saponins that are poorly absorbed as such. They have to be stripped of sugar units by the gut microbiota to give the “minor” ginsenosides, most notably ginsenoside F2 and Compound K (CK) – that actually reach the bloodstream. Because microbiome composition differs from person to person, so does the amount of CK a given consumer produces from the same ginseng dose.
The second problem is taste. Ginseng saponins are intensely bitter, which limits how much extract can go into beverages, gummies, stick packs and other consumer-friendly formats.
Bioconversion before consumption
FermenGIN® addresses the first problem by doing the gut microflora’s job in the factory. According to BTC Corporation, Korean red ginseng extract is enzymatically bioconverted so that a significant part of the major ginsenosides is already transformed into more readily absorbed minor ginsenosides, including F2 and Compound K, before the product is ever swallowed. The aim is a more consistent ginsenoside exposure that depends less on the individual’s gut flora.
The company cites human pharmacokinetic data showing significantly greater systemic exposure to key ginsenosides compared with conventional red ginseng. A published single-dose study in 13 healthy Korean men compared 5 g of conventional red ginseng with the bioconverted extract (FermenGIN®, supplied by BTC Corporation) and followed the plasma profiles.
The role of cyclodextrin
The second problem is solved with a well-proven tool: γ-cyclodextrin microencapsulation. BTC states that the γ-CD technology reduces the characteristic bitterness of ginseng, giving a more formulation-friendly sensory profile, and also contributes to improved bioavailability.
The choice of γ-cyclodextrin is a logical one. Ginsenosides are bulky triterpenoid (dammarane-type) glycosides, and the eight-membered γ-CD ring offers a wider cavity than β-CD for accommodating the steroid-like aglycone. Earlier work from Japan illustrates the point: in a rat study of Compound K complexes, the 1:1 CK/γ-CD complex had a stability constant roughly 18 times higher than the corresponding β-CD complex (about 1.5 × 10⁵ M⁻¹ vs. 8.2 × 10³ M⁻¹), dissolved faster, and gave higher Cmax and AUC values than either free CK or the β-CD complex.
Taste masking of bitter saponins and polyphenols is one of the classic food applications of cyclodextrins: by hosting the hydrophobic part of the bitter molecule in the cavity, the CD reduces its interaction with taste receptors. γ-CD is particularly attractive for nutraceuticals because it is readily digested by salivary and pancreatic amylases, has GRAS status in the US and is approved as a food additive (E 458) in the EU.
Regulatory and commercial status
FermenGIN® has been the subject of a US FDA New Dietary Ingredient notification. BTC also highlights comprehensive safety testing and a three-year shelf life, and positions the ingredient for dietary supplements and functional foods and beverages. The new white paper was published on October 16, 2026 and is being promoted through Nutraceuticals World and SupplySide.
Conclusion
FermenGIN® is a nice example of a trend we have been following for years: cyclodextrins as a quiet enabling technology in botanical ingredients. The bioconversion step does the heavy lifting on the pharmacology, but it is γ-cyclodextrin that makes the product palatable enough to be used in mainstream formats and the literature on CK/γ-CD inclusion complexes suggests it may add a solubility and absorption benefit as well.
Sources
Ginsenoside Compound K: Insights into Recent Studies on Pharmacokinetics and Health-Promoting Activities, Biomolecules 2020, 10, 1028
BTC Corporation: FermenGIN® – Bioavailable Ginsenoside, Powered by Bioconversion (Nutraceuticals World, Oct 16, 2026)
Bioavailable ginsenoside powered by bioconversion (SupplySide)